Plain English Summary
Background and study aims
Heart failure is caused by the heart muscle becoming weak or stiff and failing to pump enough blood around the body. It significantly reduces quality of life and life expectancy. The costs to the NHS are high due to frequent hospitalisation and GP visits. Heart failure is a common problem in primary care, but diagnosis is difficult and GPs must decide which patients need further tests. Heart failure can be diagnosed by ultrasound (an echocardiogram) but it is expensive and limited. Therefore, GPs rely on less effective tests, resulting in under-diagnosis. Accurate diagnosis, appropriate treatment and cost−effective use of NHS resources are needed to improve quality of life and life expectancy. However, there is uncertainty in these areas. We aim to find out if a clinical decision rule (CDR) can help GPs determine which patients should be referred for an echocardiogram and if it is cost−effective. The study will tell us if a simple rule involving symptoms, physical examination and blood testing can be used for better diagnosis and targeting of further diagnostic tests for heart failure, helping to improve quality of care and save money.
Who can participate?
Patients aged 55 or over visiting their GP with new symptoms of breathlessness, lethargy (tiredness) or ankle oedema (swelling)
What does the study involve?
The GP refers all patients for chest x−ray (as usual), and then to a central research clinic. Information on symptoms and quality of life are collected, and patients undergo an electrocardiogram (measuring the electrical activity of the heart), an echocardiogram (an ultrasound scan of the heart), and provide a blood sample. We want to find out whether the CDR can correctly identify all cases with heart failure. We follow-up patients after 6 and12 months to collect medical and quality of life information.
What are the possible benefits and risks of participating?
Not provided at time of registration
Where is the study run from?
University of Oxford (UK)
When is the study starting and how long is it expected to run for?
April 2011 to June 2014
Who is funding the study?
Medical Research Council (MRC)/National Institute of Health Research (NIHR) (UK) - Efficacy and Mechanism Evaluation (EME) Programme (UK)
Who is the main contact?
Prof Richard Hobbs
Trial website
Additional identifiers
EudraCT number
ClinicalTrials.gov number
Protocol/serial number
09/160/13
Study information
Scientific title
The REFer for EchocaRdiogram, clinical decision rule and N-terminal pro-B-type natriuretic peptide (NT-proBNP) in the diagnosis of heart failure: a prospective validation study
Acronym
REFER
Study hypothesis
The clinical decision rule (CDR) will discriminate between patients who have sufficiently high probability of heart failure (HF) that they should be referred for echo and those who should have a natriuretic peptide (NP) test first, with referral for echo dependent upon the natriuretic peptide results.
Ethics approval
The South Birmingham Research Ethics Committee, 15/10/2009
Study design
Multicentre prospective observational diagnostic validation study
Primary study design
Observational
Secondary study design
Diagnostic validation study
Trial setting
GP practices
Trial type
Diagnostic
Patient information sheet
Not available in web format, please use the conatct details below to request a patient information sheet
Condition
Heart failure
Intervention
The general practitioner (GP) will have arranged for all patients to receive a chest x-ray when consenting patients for referral (as is usual practice). Within 7 days of referral, the research assessment clinical team will obtain written informed consent, collect baseline demographics, administer quality of life questionnaires (EQ-5D and SF12), clinically assess patients, perform a 12-lead electrocardiogram (ECG) and Echo and take blood for N-terminal pro b-type natriuretic peptide (NT-proBNP), along with creatinine for a renal dysfunction test, calculating an estimated Glomerular Filtration Rate (eGFR) (serum profile)
Intervention type
Other
Phase
Not Applicable
Drug names
Primary outcome measure
1. Test performance of the CDR, estimating the sensitivity and specificity, positive predictive value (PPV) and negative predictive value (NPV) of the CDR for diagnosis of HF in symptomatic patients presenting with shortness of breath, lethargy or ankle oedema of over 48 hours duration
2. Test performance of the diagnostic accuracy of NT-proBNP for diagnosis of HF in symptomatic patients, including sensitivity, specificity, PPV and NPV
3. Proportion of patients with left ventricular systolic dysfunction (LVSD) or not, (ejection fraction < 40%) and HF or not
Secondary outcome measures
1. Combination of the CDR and NT-proBNP
2. Modelling of CDR test performance and epidemiological data to ascertain the most cost-effective strategy in the diagnosis of HF in primary care, incorporating data on quality of life (EQ-5D and SF12 widely used questionnaires), clinical events and health care resource use
3. Reliability of GP clinical judgment alone in diagnosing HF
4. Reliability of individual clinical features
5. Reliability of ECG interpretation
6. Estimation of the best performing cut-offs for NT-proBNP to maximise diagnostic yield and for maximising cost-effective referrals
7. Determine the use of variable echocardiographic markers of diastolic function in the diagnosis of HF with preserved ejection fraction
Overall trial start date
01/04/2011
Overall trial end date
01/06/2014
Reason abandoned (if study stopped)
Eligibility
Participant inclusion criteria
Current inclusion criteria as of 12/12/2011:
1. All patients 55 years of age or over presenting to their GP with new onset symptoms of breathlessness, lethargy or ankle oedema of over 48 hours duration, with no obvious recurrent, acute or self-limiting cause
2. Able to give informed consent
Previous inclusion criteria:
1. All patients 55 years of age or over presenting to their GP with new onset symptoms of breathlessness, lethargy or ankle oedema of over 48 hours duration, with no obvious acute and self-limiting cause
2. Able to give informed consent
Participant type
Patient
Age group
Adult
Gender
Both
Target number of participants
500
Participant exclusion criteria
Current exclusion criteria as of 12/12/2011
1. All patients with known pre-existing heart failure or left ventricular systolic dysfunction of any cause. However, patients with a pre-existing label of heart failure but without objective evidence (i.e. echocardiography) of this will not be excluded
2. Severe symptoms requiring urgent assessment or stabilisation (e.g. breathless at rest, hypotension, confusion)
3. Obvious clinically determined alternative diagnoses such as chest infection, exacerbation of chronic obstructive pulmonary disease or asthma
4. Recent acute coronary syndrome (within 60 days)
5. Major co-morbidity or other alternative diagnoses of no obvious acute and self-limiting cause (e.g. malignancy, severe respiratory disease, renal diagnosis, mental health problem)
6. Unable to provide informed consent
Previous exclusion criteria
1. All patients with known pre-existing heart failure or left ventricular systolic dysfunction of any cause. However, patients with a pre-existing label of heart failure but without objective evidence (i.e. echocardiography) of this will not be excluded
2. Severe symptoms requiring urgent assessment or stabilisation (e.g. breathless at rest, hypotension, confusion)
3. Obvious clinically determined alternative diagnoses such as chest infection, exacerbation of chronic obstructive pulmonary disease or asthma
4. Recent acute coronary syndrome (within 60 days)
5. Major co-morbidity or other alternative diagnoses of no obvious acute and self-limiting cause (e.g. active malignancy, severe respiratory disease, renal diagnosis, severe psychiatric disease)
6. Unable to provide informed consent
Recruitment start date
01/04/2011
Recruitment end date
01/06/2014
Locations
Countries of recruitment
United Kingdom
Trial participating centre
University of Oxford
Oxford
OX1 2ET
United Kingdom
Funders
Funder type
Government
Funder name
Medical Research Council (MRC)/National Institute of Health Research (NIHR) (UK) - Efficacy and Mechanism Evaluation (EME) Programme (ref: 09/160/13)
Alternative name(s)
Funding Body Type
Funding Body Subtype
Location
Results and Publications
Publication and dissemination plan
Not provided at time of registration
Intention to publish date
Participant level data
Not provided at time of registration
Basic results (scientific)
Publication list
2012 protocol in: http://www.ncbi.nlm.nih.gov/pubmed/23110558
Publication citations
-
Protocol
Tait L, Roalfe AK, Mant J, Cowie MR, Deeks JJ, Iles R, Barton PM, Taylor CJ, Derit M, Hobbs FD, The REFER (REFer for EchocaRdiogram) protocol: a prospective validation of a clinical decision rule, NT-proBNP, or their combination, in the diagnosis of heart failure in primary care. Rationale and design., BMC Cardiovasc Disord, 2012, 12, 97, doi: 10.1186/1471-2261-12-97.